Celliaz

Executive Summary

Celliaz is a preclinical-stage biotechnology company based in Cambridge, Massachusetts, founded in 2020, focused on developing cell therapy innovations for regenerative medicine and tissue repair. The company operates in the rapidly advancing field of cell therapy, leveraging proprietary technologies to address unmet needs in tissue regeneration. As a private, early-stage entity with limited public financial and pipeline data, Celliaz's progress is primarily assessed through its preclinical milestones and potential for future clinical entry. The company's near-term value hinges on advancing its lead candidate toward IND-enabling studies and securing partnerships or funding to support its research and development activities.

Upcoming Catalysts (preview)

• Q1 2027IND Filing for Lead Cell Therapy Candidate40% success
• Q4 2026Presentation of Preclinical Efficacy Data at Major Conference60% success
• Q3 2026Series A Financing Round Closure50% success